TransMedics Group Reports 38% Revenue Growth to $157.4M and $0.92 EPS in Q2 2025

Reuters

2025/07/31

TransMedics Group Reports 38% Revenue Growth to $157.4M and $0.92 EPS in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025

TransMedics Group Inc. announced its financial results for the second quarter of 2025, reporting a total revenue of $157.4 million, marking a 38% increase compared to the same period in 2024. The company generated a net income of $34.9 million, or $0.92 per fully diluted share, during this period. The company also updated its financial outlook for the full year 2025, raising its revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year's revenue. In addition to its financial performance, TransMedics received conditional Investigations Device Exemption $(IDE)$ approval from the U.S. Food and Drug Administration to initiate the Next-Gen OCS™ Lung trial. The company also launched the OCS NOP digital ecosystem, NOP ACCESS™, across major NOP™ transplant programs in the United States. President and CEO Waleed Hassanein expressed confidence in the company's strategy and emphasized the focus on achieving 10,000 US NOP transplants by 2028 while continuing to invest in future growth opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE41080) on July 30, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555024822"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555024822\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555024822?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555024822","market":"us","top_or_hot":-1,"title":"TransMedics Group Reports 38% Revenue Growth to $157.4M and $0.92 EPS in Q2 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransMedics Group Reports 38% Revenue Growth to $157.4M and $0.92 EPS in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TMDX\">TransMedics Group Inc.</a> announced its financial results for the second quarter of 2025, reporting a total revenue of $157.4 million, marking a 38% increase compared to the same period in 2024. The company generated a net income of $34.9 million, or $0.92 per fully diluted share, during this period. The company also updated its financial outlook for the full year 2025, raising its revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year's revenue. In addition to its financial performance, TransMedics received conditional Investigations Device Exemption <a href=\"https://laohu8.com/S/IDE\">$(IDE)$</a> approval from the U.S. Food and Drug Administration to initiate the Next-Gen OCS™ Lung trial. The company also launched the OCS NOP digital ecosystem, NOP ACCESS™, across major NOP™ transplant programs in the United States. President and CEO Waleed Hassanein expressed confidence in the company's strategy and emphasized the focus on achieving 10,000 US NOP transplants by 2028 while continuing to invest in future growth opportunities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE41080) on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransMedics Group Reports 38% Revenue Growth to $157.4M and $0.92 EPS in Q2 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransMedics Group Reports 38% Revenue Growth to $157.4M and $0.92 EPS in Q2 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-31 04:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransMedics Group Reports 38% Revenue Growth to $157.4M and $0.92 EPS in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TMDX\">TransMedics Group Inc.</a> announced its financial results for the second quarter of 2025, reporting a total revenue of $157.4 million, marking a 38% increase compared to the same period in 2024. The company generated a net income of $34.9 million, or $0.92 per fully diluted share, during this period. The company also updated its financial outlook for the full year 2025, raising its revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year's revenue. In addition to its financial performance, TransMedics received conditional Investigations Device Exemption <a href=\"https://laohu8.com/S/IDE\">$(IDE)$</a> approval from the U.S. Food and Drug Administration to initiate the Next-Gen OCS™ Lung trial. The company also launched the OCS NOP digital ecosystem, NOP ACCESS™, across major NOP™ transplant programs in the United States. President and CEO Waleed Hassanein expressed confidence in the company's strategy and emphasized the focus on achieving 10,000 US NOP transplants by 2028 while continuing to invest in future growth opportunities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE41080) on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"Transmedics Group","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL27g4xN:1","article_id":"2555024822","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555024822","pubTimestamp":1753906139,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TransMedics Group Inc. announced its financial results for the second quarter of 2025, reporting a total revenue of $157.4 million, marking a 38% increase compared to the same period in 2024. The company generated a net income of $34.9 million, or $0.92 per fully diluted share, during this period. The company also updated its financial outlook for the full year 2025, raising its revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year's revenue. In addition to its financial performance, TransMedics received conditional Investigations Device Exemption  approval from the U.S. Food and Drug Administration to initiate the Next-Gen OCS Lung trial. The company also launched the OCS NOP digital ecosystem, NOP ACCESS, across major NOP transplant programs in the United States. President and CEO Waleed Hassanein expressed confidence in the company's strategy and emphasized the focus on achieving 10,000 US NOP transplants b","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"Transmedics Group"},"translate_title":"TransMedics Group报告2025年第二季度收入增长38%，达到1.574亿美元，每股收益0.92美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":0.9},"content_text":"TransMedics Group Reports 38% Revenue Growth to $157.4M and $0.92 EPS in Q2 2025\n    \n\nTransMedics Group Inc. announced its financial results for the second quarter of 2025, reporting a total revenue of $157.4 million, marking a 38% increase compared to the same period in 2024. The company generated a net income of $34.9 million, or $0.92 per fully diluted share, during this period. The company also updated its financial outlook for the full year 2025, raising its revenue guidance to a range of $585 million to $605 million, reflecting a 35% growth at the midpoint compared to the previous year's revenue. In addition to its financial performance, TransMedics received conditional Investigations Device Exemption $(IDE)$ approval from the U.S. Food and Drug Administration to initiate the Next-Gen OCS™ Lung trial. The company also launched the OCS NOP digital ecosystem, NOP ACCESS™, across major NOP™ transplant programs in the United States. President and CEO Waleed Hassanein expressed confidence in the company's strategy and emphasized the focus on achieving 10,000 US NOP transplants by 2028 while continuing to invest in future growth opportunities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE41080) on July 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}